Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis

  • Fernanda de Oliveira Demitto,
  • Renata Claro Ribeiro do Amaral,
  • Flaviane Granero Maltempe,
  • Vera Lúcia Dias Siqueira,
  • Regiane Bertin de Lima Scodro,
  • Mariana Aparecida Lopes,
  • Katiany R. Caleffi-Ferracioli,
  • Pedro Henrique Canezin,
  • Rosilene Fressatti Cardoso

The graph legends for Figs 1 and 2 are incorrect. The symbols for RIF and VP are switched. Please see the complete, correct Figs 1 and 2 here.

thumbnail
Fig 1. Time-kill curve of the Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates 71A, 18, 19, 109, 3614, and 64A exposed to rifampicin (RIF), verapamil (VP), and RIF+VP combination for 7 days at 35–37°C.

https://doi.org/10.1371/journal.pone.0133343.g001

thumbnail
Fig 2. Fluorometry assay.

Accumulation of EtBr in the Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates 71A, 18, 19, 109, 3614, and 64A. The mycobacteria were loaded with 0.25 μg/ml EtBr in the presence of 0.5 × MIC of verapamil (VP), rifampicin (RIF), and RIF+VP combination for 7 days at 35–37°C.

https://doi.org/10.1371/journal.pone.0133343.g002

Reference

  1. 1. Demitto FdO, do Amaral RCR, Maltempe FG, Siqueira VLD, Scodro RBdL, Lopes MA, et al. (2015) In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis. PLoS ONE 10(2): e0116545. pmid:25689777